Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 5/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.40 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18742067 | 0.93 | LMNA (0.45) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18742090 | 0.84 | LMNA (0.43) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18744137 | 0.84 | LMNA (0.50) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL13176571 | 0.84 | LMNA (0.50) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL1331888 | 0.83 | STING1 (0.57) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL19954155 | 0.83 | STING1 (0.57) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL16561105 | 0.83 | STING1 (0.57) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL17826621 | 0.82 | LMNA (0.47) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL22589417 | 0.81 | RXFP1 (0.42) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL23105029 | 0.81 | POLG (0.40) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170101431-A1 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-04-13 | — | — | US | disclosed |
| US-20170101431-A1 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101431-A1 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | TYMP, NSUN2, PNP | LMNA 544/4885THRB 4618/4885MTOR 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.